Gain Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | GAIN THERAPEUTICS, INC. | |
|---|---|---|
| | (Registrant) | |
| Date: March 26, 2024 | By: | /s/ Matthias Alder |
| | | Matthias Alder |
| | | Chief Executive Officer |
| | | (Principal Executive Officer) |
| | | |
| Date: March 26, 2024 | By: | /s/ Gianluca Fuggetta |
| | | Gianluca Fuggetta |
| | | Finance Vice President |
| | | (Principal Financial Officer and Principal Accounting Officer) |
POWER OF ATTORNEY
We, the undersigned directors and officers of Gain Therapeutics, Inc., hereby severally constitute and appoint Matthias Alder and Gianluca Fuggetta, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| | | |
|---|---|---|
| Dated: March 26, 2024 | | /s/ Matthias Alder |
| | | Matthias AlderChief Executive Officer and Director (Principal Executive Officer) |
| | | |
| Dated: March 26, 2024 | | /s/ Gianluca Fuggetta |
| | | Gianluca FuggettaFinance Vice President(Principal Financial Officer and Principal Accounting Officer) |
| | | |
| Dated: March 26, 2024 | | /s/ Khalid Islam |
| | | Khalid IslamChairman of the Board of Directors |
| | | |
| Dated: March 26, 2024 | | /s/ Dov Goldstein |
| | | Dov GoldsteinDirector |
| | | |
| Dated: March 26, 2024 | | /s/ Hans Peter Hasler |
| | | Hans Peter HaslerDirector |
| | | |
| Dated: March 26, 2024 | | /s/ Gwen Melincoff |
| | | Gwen Melincoff Director |
| | | |
| Dated: March 26, 2024 | | /s/ Claude Nicaise |
| | | Claude NicaiseDirector |
| | | |
| Dated: March 26, 2024 | | /s/ Eric I. Richman |
| | | Eric I. RichmanDirector |
| | | |
| Dated: March 26, 2024 | | /s/ Jeffrey Riley |
| | | Jeffrey RileyDirector |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.